Kura Oncology officer proposes $108K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. (KURA) reports that Brian Powl, an officer, filed a notice for the proposed sale of 15,254 common shares on approximately November 17, 2026, with an aggregate market value of $108,150.86. The shares were acquired from the issuer as restricted stock units on November 13, 2026. The notice lists May 22, 2026 as the plan adoption or instruction date for reliance on Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior KURA sales did Brian Powl report in the notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.